The standard treatment for superficial TCC of the bladder is the endoscopic
resection of all visible tumours. Transurethral resection (TUR) may fail to control superficial disease,
especially in patients with higher tumour stages (T1), in addition
to the high recurrence rate.
To evaluate the role of a second transurethral resection (early re-resection) in reducing the high
recurrence rate of T1 bladder tumours .
Bladder cancer is the second most common urogenital tumor. The stage, grade,
number and diameter of urinary bladder cancer is an important factors in determining prognosis of the
disease. Early diagnosis and proper treatment are also critical to im
prove survival.
This retrospective study was performed to determine the clinico-pathological features of primary bladder
cancer at first presentation at Damascus University hospitals.
Radical cystectomy is the most effective therapeutic approach for patients with
muscle-invasive bladder cancer. Due to the incidence of sexual and continence complications associated
with this procedure, alternative techniques such as cystectomy wi
th partial prostatectomy have been
described in selected cases in order to reduce complications.
To evaluate the possible oncological risks of prostate-sparing cystectomy, and to determine the associated
pathological findings in the prostate for patients with invasive bladder cancer treated by radical
cystoprostatectomy.
Bladder cancer is the most common malignancy of the urinary
tract, and has the fastest rate of recurrence which gives it high
prevalence of tumors all over the world. Early diagnosis is very
important for treatment efficacy, prevent tumor progress
ion and
prolong survival period, so many urinary markers have been
studied but early diagnosis of carcinoma of bladder remains a
challenge. Survivin is a member of the inhibitor of apoptosis
protein family (IAPs), whose irregular expression is associated with
tumor cell proliferation, progression, angiogenesis, therapeutic
resistance, and poor prognosis.
